SGLT2 inhibitors reduced the risk of all-cause death (RR 0.89; 95% CI: 0.85–0.94; I2 = 32%; p < 0.01), CV death (RR 0.87; 95% CI: 0.82–0.93; I2 = 11%; p < 0.01), MACEs (RR 0.89; 95% CI: 0.84–0.94; I2 = 46%; p < 0.01), HHF (RR 0.70; 95% CI: 0.66–0.74; I2 = 0%; p < 0.01), and AKI (RR 0.81; 95% CI: 0.73–0.90; I2 = 0%; p < 0.01) but increased the risk of DKA (RR 2.56; 95% CI: 1.72–3.80; I2 = 0%; p < 0.01). The gene discussed is SLC5A2; the disease is acute kidney injury.